CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
birch pollen subcutaneous immunotherapydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01985542
NCT01985542N/ACompleted
CompareCT.gov

The Molecular Biological Effects of Immunotherapy in the Nose

Helsinki University Central Hospital·interventional·Posted Nov 15, 2013·Updated Jun 10, 2021

In Brief

A clinical study evaluating birch pollen subcutaneous immunotherapy for Rhinitis, Allergic, Seasonal. Completed, enrolled 16 participants.

Detailed Summary

Allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and other environmental insults. About 20 % of the European population suffers from pollen allergies. Birch pollen allergic rhinitis is the most common allergic disease in the Scandinavia and it exists widely also in the Central Europe. Suffering and high costs of pollen allergies may be reduced by understanding the molecular biology of the nasal barriers during allergic response. Our aim is to observe the effect of season and birch pollen immunotherapy on the molecular biology of nasal epithelium and the microbiome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Seasonal
Countries--
CollaboratorsUniversity of Helsinki, Finnish Institute of Occupational Health

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 15, 2013
Enrollment StartMay 1, 2011
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.6 years ago

Interventions

birch pollen subcutaneous immunotherapydrug

birch pollen subcutaneous immunotherapy